Biotech - Cell Therapy
•103 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (103)
%
| Company | Market Cap | Price |
|---|---|---|
|
Biotech - Cell Therapy: post-merger pipeline includes allogeneic cell therapies (IsletRx for Type 1 diabetes, AstroRx for ALS).
|
$1.73M |
$1.76
-4.35%
|
|
CER-T is an engineered T-cell therapy platform, a core cell-based therapy offering.
|
$1.28M |
$3.31
-20.24%
|
|
Pipeline includes cell therapies (HemaXellarate, dCellVax, tCellVax, DuroCAR), indicating Cell Therapy manufacturing/development.
|
$703985 |
$0.02
-41.18%
|
Showing page 2 of 2 (103 total stocks)
Loading industry metrics...
Loading comparison data...
